All In Biotech

Drug Trial Radar · NCT03687333

Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa Treatment

A Single Arm, Prospective, Open-label, Multi-center Study to Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa Treatment

Last checked: Nov 20, 2026Latest source record: Apr 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

Dec 4, 2018

Primary completion

Dec 30, 2020

Study completion Dec 30, 2020

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Sep 27, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 0 months, up to 12 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To evaluate effect of 52-week treatment with Alglucosidase Alfa in the extension of survival and improvement of cardiomyopathy measured by Left Ventricular Mass Index in Chinese patients with infantile-onset Pompe Disease. Secondary Objectives: * To observe the improvement of physical growth, motor and cognitive development of 52-week treatment with Alglucosidase Alfa in infantile-onset Pompe Disease from the baseline. * To observe the efficacy on survival free of invasive ventilation, use of any ventilation support of 52- week treatment with Alglucosidase Alfa in Chinese patients with infantile-onset Pompe Disease. * To evaluate the safety and tolerability of Alglucosidase Alfa in Chinese patients with infantile-onset Pompe Disease.

Conditions

  • Glycogen Storage Disease Type II

Interventions

  • ALGLUCOSIDASE ALFA (MYOZYME)Drug

    Pharmaceutical form: cake or powder for injection Route of administration: intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SurvivalTime frame: at week 52
  2. Left Ventricular Mass Index (LVMI)Time frame: at week 52

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Investigational site number

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.